Press Releases

BioIVT Appoints Steven W. Louie as Director of Transporter Sciences

May 9, 2018, 10:24 AM by Michael Croft
WESTBURY, NY - May 9, 2018 - BioIVT, a leading provider of biospecimens and related services, today announced that Steven W. Louie has joined the company as Director of Transporter Sciences
BioIVT continues to expand capabilities in its ADME Tox Research Services Group

WESTBURY, NY - May 9, 2018 - BioIVT, a leading provider of biospecimens and related services, today announced that Steven W. Louie has joined the company as Director of Transporter Sciences. In his new role, Louie will lead the expansion of BioIVT’s hepatic transporter business. His areas of responsibility will include scientific oversight of BioIVT’s in vitro hepatic transporter products and research services, and study design to provide in vivo-relevant data suitable for lead selection and regulatory filings.

Christopher Black, PhD, Senior Vice President ADME Tox at BioIVT, commented, “We are thrilled to have someone of Steven’s caliber and ‘big pharma’ experience join the team. We are committed to providing excellence in ADME Tox services and Steven adds to our deep bench of scientific expertise in hepatic transporters. We know our clients will benefit from working with Steven.”

Louie has more than 20 years’ experience in the pharmaceutical industry and has led research programs at GSK, Merck, and Amgen. At Amgen, he was instrumental in developing higher throughput transporter tools to support early discovery and development projects in the department of Pharmacokinetics and Drug Metabolism.

His efforts have led to more than 40 IND-enabling transporter reports and recent US Food and Drug Administration/European Medicines Agency drug approvals for Corlanor®, Kryprolis®, and Parsabiv™. His area of research includes in vitro to in vivo extrapolation of transporter-mediated drug-drug interactions.

“I am excited to be joining the excellent team at BioIVT,” said Louie. “My new colleagues at BioIVT pioneered research in hepatic transporters and we have previously collaborated on numerous projects. I am looking forward to working with BioIVT’s global clients on their research programs.”

Louie was elected Chair of the American Association of Pharmaceutical Scientists (AAPS) Drug Transport Focus Group in 2016 and will complete his term in 2018. He also served as the Organizing Chair of the 2018 AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside.

In 2017, the AAPS Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) Section honored Louie with the PPDM Service Award.

Louie has organized, moderated, and taught several AAPS symposia and the Transporter Bootcamp: Back to Basics Workshop. He also developed and launched the AAPS eLearning Services Course: Transporter Knowledge for New Frontiers https://www.pathlms.com/aaps/courses/3461. His work has been published in book chapters, peer-reviewed journals, and the AAPS Newsmagazine and Blogs.

Louie received an MS in microbiology and immunology from the University of Iowa.

Corlanor is a registered trademark of Biofarma, Kryprolis® is a registered trademark of Onyx Pharmaceuticals, Inc. and Parsabiv™ is a trademark of Amgen Inc.

About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease-state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.